Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    15642080 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: MK0653, ezetimibe / Duration of Treatment: 30 Weeks;   Drug: Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks

Indicates status has not been verified in more than two years